Showing posts with label medical devices. Show all posts
Showing posts with label medical devices. Show all posts

Monday, March 18, 2013

N-of-8 application: Exposing unexpected global challenges and opportunities


By its nature, research in health, science, and technology dictates thinking outside the “box” in new and creative ways, seeking fresh perspectives and continuously tapping new innovations for cost-effective and environment-friendly products.

Medical research goes hand in hand with the advent of globalization in the economy, commerce, and societal trends and values. International collaboration in medical research will create fertile conditions for research innovations, understanding, and common solutions to common problems.

The basic logic of N-of-8 New Product Conception applies branding excellence at the international level that is compatible with the global research cooperation in research, development, and scientific activities.

Using N-of-8 should mean that significantly greater financial resources and human intellectual talent can be concentrated on solving the most significant health problems – and increase the timely application of new approaches that would reduce morbidity and mortality in the most significant numbers worldwide.

Obviously, yet importantly, in today’s real-time knowledge sharing, an N-of-8 approach can give a brand team in multiple markets simultaneous access to new product ideas to address similarly demands and issues – motivating the team to more global integration,  more competitiveness, and greater sustainability in product usage.


To work towards creating such vision, N-of-8 can:

Create enabling procedures – the frameworks for research that take into consideration the global market in fostering innovations. Enabling procedures take into consideration the mobility of scientists across borders.

Mobilize human capital – to focus both scientists and marketers, strengthening their collaborative capacity.  Idea generation with cultural competency and sensitivity can lead to successful cross-cultural collaboration.

Build collaboration mechanisms and joint programs – to clearly define goals and processes that lower barriers to product development and enhance synergy.

Systematically address the main barriers that are often issues that lead team down “blind alleys” and block the discussion and dissemination of new ideas and prototypes.  N-of-8 can promote global standardization and harmonization of research knowledge.

Improve idea management and sharing – with a model, tools, and structure for global brand development, creating common standards for documentation and collaboration practices.

Tuesday, March 12, 2013

7 areas of innovative solutions in medical textiles


From Fast Company
Textiles and innovation aren't two words that generally go hand in hand. That's about to change, according to the folks at the European Center of Innovative Textiles (CETI), in Lille, France.

The organization inaugurated its new headquarters last year.  Its goal is creating better, more high-tech solutions across a number of industries. Their current projects show that potential.

Specific to health care, CETI is working to develop new fabric for wound dressing, in which medicine, antivirals, and antibacterials are already integrated into the fibers. Looking further to the future, the organization envisions nonwoven textiles that can be used as a "seed" to rebuild tissue.

Medical, sport & leisure, hygiene, and protection represent over 25% of technical textiles market in value and volume. 

Medical textiles offer innovation solutions in the following application sectors:
  1. wound care,
  2. regenerative medicine,
  3. filtration,
  4. hospital hygiene,
  5. implants,
  6. orthoses and
  7. personal independence

Tuesday, November 29, 2011

Is the FDA promoting or precluding medical innovation?

I have been working with a number of medical device clients lately, and I've been struck by the frustrating delays in bringing new innovative products to market.

"U.S. investment in medical devices is falling...yet the FDA is demanding more drug-like trials for devices, causing many of the delays in getting new products to U.S. consumers," says Dr. Scott Gottlieb, a leading physician and deputy commissioner of the FDA from 2005-2007.

In a recent opinion piece in The Wall Street Journal, Gottleib refers to data from PricewaterhouseCoopers and the National Venture Capital Association showing the number of newly started, venture-backed medical-device companies fell to 60 in 2010 from 118 in 2008. "The magnitude of these declines dwarfs those seen in other entrepreneurial sectors. It can't reasonably be ascribed to the struggling economy alone," he asserts.

Gottleib references a 2011 study by the Boston Consulting Group of European device approvals that suggests that Europe's more expedited process is just as rigorous and safe as the FDA's. 

"Devices are also tools in the hands of physicians. The benefits of a device are ultimately dependent on how it is used by a physician," writes Gottleib. "A stethoscope, for example, only needs to show that it can enable a doctor to hear heart sounds. A stethoscope should not have to prove that using it can reduce the complications from heart failure."

He concludes, "This is no way to run a regulatory process if the FDA is serious about promoting medical innovation and advancing the public health."

Click here to read his entire article at http://online.wsj.com